Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
2
×
Tags
akcea therapeutics
biotech
2
×
boston blog main
boston top stories
fda
inotersen
2
×
life sciences
national blog main
national top stories
new york blog main
new york top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
2025
ad-comm
affimed
allogene therapeutics
alnylam pharmaceuticals
amicus therapeutics
approval
apremilast
barry greene
base editing
bio
biogen
biome
blueprint medicineas
boston
boston university
boulder/denver blog main
boulder/denver top stories
briefing docs
car-t
celgene
cervical cancer
clinical study
clinical trial
clinical trials
What
ago
allogene
alnylam
approve
awaits
bio
biological
cancer
crispr
crossed
decades
decision
discovered
diversity
fda
fingers
friday
historic
hot
immunotherapy
investors
ipo
juno
medicine
million
nearly
new
patients
remains
rna
roundup
shares
snapped
therapeutics
ticket
time
trick
uses
utero
years
Language
Current search:
inotersen
×
biotech
×
photo
×
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision